Tristetraprolin is a prognostic biomarker for poor outcomes among patients with low-grade prostate cancer

Robert J. Rounbehler*, Anders E. Berglund, Travis Gerke, Mandeep M. Takhar, Shivanshu Awasthi, Weimin Li, Elai Davicioni, Nicholas G. Erho, Ashley E. Ross, Edward M. Schaeffer, Eric A. Klein, R. Jeffrey Karnes, Robert B. Jenkins, John L. Cleveland, Jong Y. Park, Kosj Yamoah

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

9 Scopus citations

Fingerprint

Dive into the research topics of 'Tristetraprolin is a prognostic biomarker for poor outcomes among patients with low-grade prostate cancer'. Together they form a unique fingerprint.

Medicine and Dentistry

INIS

Pharmacology, Toxicology and Pharmaceutical Science

Biochemistry, Genetics and Molecular Biology

Immunology and Microbiology